Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

Cancer

Volumn 101, Issue 6, 2004, Pages 1414-1419

  Karbasian Esfahani, Merat ^a   Wiernik, Peter H ^a,b   Novik, Yelena ^a   Paietta, Elisabeth ^a   Dutcher, Janice P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Our Lady of Mercy Cancer Center   (United States)

Author keywords

Acute lymphocytic leukemia; Cytosine arabinoside; Idarubicin; Recurrent and refractory acute lymphocytic leukemia

Indexed keywords

ANTIBIOTIC AGENT; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD CELL COUNT; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CARDIOTOXICITY; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPIOID INDUCED EMESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IDARUBICIN; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 4444346719     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20494     Document Type: Article

References (34)

1. Garicia-Manero G, Faderl S, Giles F, et al. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002;87:804-807.
2. Giona F, Testi AM, Amadori S, et al. Idarubicin and high dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol. 1990;1:51-55.
3. Testi AM, Moleti ML, Giona F, et al. A single high dose of idarubicin combined with high dose ARAC (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Haematologica. 1997;82:664-667.
4. Mazza JJ, Leong T, Rowe JM, et al. Treatment of adult patients with acute lymphocytic leukemia in relapse. Leuk Lymphoma. 1996;20:317-319.
5. Abromowitch M, Bowman WP, Ochs J, et al. Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia. J Clin Oncol. 1985; 3:789-792.
6. Krischer J, Land VJ, Divin CI, et al. Evaluation of AMSA in children with acute leukemia: a pediatric oncology group study. Cancer. 1984;54:1256-1259.
7. Ryan DH, Brickers JN, Vial RH, et al. Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study. Cancer Treat Rep. 1980;64:869-872.
8. Herzig BH, Wolff SN, Lazanes HM, et al. High dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62: 361-369.
9. Weiss MA, Drullinsky P, Maslak P. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1988;12:856-858.
10. Weiss MA. Treatment of adult patients with relapsed or refractory acute lymphblastic leukemia. Leukemia. 1997; 11(Suppl. 4):S28-S30.
11. Carella AM, Pungolino E, Piatti G, et al. Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias. Eur J Haematol. 1989;43:309-313.
12. Bernstein MI, Abshire TC, Pollock BH, et al. Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1997;19:68-72.
13. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-819.
14. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer, Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591-598.
15. Hoelzer D, Gokbuget N. Diagnosis and treatment of adult acute lymphoblastic leukemia. In: Wiernik PH, Dutcher JP, Goldman J, Kyle R, editors. Neoplastic diseases of the blood, 4th edition. Cambridge: Cambridge University Press, 2003: 273-305.
16. Belaud-Rotureau MA, Durrieu F, Labroille G, et al. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. Leukemia. 2000;14:1266-1275.
17. Wiernik PH, Banks PL, Case DC Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-319.
18. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
19. Cerososimo RJ. Idarubicin: an anthracycline antineoplastic agent. Clin Pharm. 1992;11:152-167.
20. Creutzig U, Kornholz D, Niemeyer CM, et al. Toxicity and effectiveness of high dose idarubicin during AML induction therapy: results of a pilot study in children. Klin Padiatr. 2002;212:163-168.
21. Barone S, Baer MR, Sait SN, et al. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. Am J Hematol. 2001;7:119-124.
22. Flasshove M, Meusers P, Schutte J, et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol 2000;79:533-542.
23. Creutzig U, Ritter J, Zimmerman M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15:348-354.
24. Hartman F, Jacobs G, Gotto H, et al. Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients. Leak Lymphoma, 2001;42:347-355.
25. Giles FJ, Faderl S, Thomas DA, et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003;21:1050-1056.
26. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003;51:87-90.
27. Fulle HH, Hellrigel KP. 4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia. Haematol Blood Transfus. 1987;30:34-35.
28. Lee ST, Jang JH, Suh HC, et al. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high risk myelodysplastic syndrome. Am J Hematol. 2001;68:237-245.
29. Weiss MA, Aliff TB, Tallman MS, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer. 2002;95:581-587.
30. Del Principe MI, Del Poeta G, Maurillo L, et al. P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukemia. Br J Haematol. 2003;121:730-738.
31. Bassan R, Chiodini B, Lerede T, et al. The role of idarubicin in adult acute lymphoblastic leukemia: from drug resistance studies to clinical application. Leukemia Lymphoma. 1997; 26(Suppl. 1):89-97.
32. Nuessler V, Gieseler F, Zwierzina H, et al. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P glycoprotein expression. Ann Hematol. 1997; 74:57-64.
33. Seeker-Walker LM, Prentice HG, Durrant J. Cytogenetics adds independent prognostic information in adults with a lymphoblastic leukemia on MRC trial UKALL XA. MRC Adult Leukemia Working Party. Br J Haematol. 1997;9:601-610.
34. Paietta E. Immunobiology of acute leukemia In: Wiernik PH, Dutcher JP, Goldman J, Kyle R, editors. Neoplastic diseases of the blood, 4th edition. Cambridge: Cambridge University Press, 2003:194-231.